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ABSTRACT: A seminal question in wildlife toxicology is whether exposure to an environmental contaminant, in particular a secondgeneration anticoagulant rodenticide, can evoke subtle long lasting effects on body condition, physiological function and survival.
Many reports indicate that non-target predators often carry residues of several rodenticides, which is indicative of multiple exposures.
An often-cited study in laboratory rats demonstrated that exposure to the second-generation anticoagulant rodenticide brodifacoum
prolongs blood clotting time for a few days, but weeks later when rats were re-exposed to the first-generation anticoagulant rodenticide
warfarin, coagulopathy was more pronounced in brodifacoum-treated rats than naïve rats exposed to warfarin. To further investigate
this phenomenon, American kestrels were fed environmentally realistic doses of chlorophacinone or brodifacoum for a week, and
following a week-long recovery period, birds were then challenged with a low-level dietary dose of chlorophacinone. In the present
study, neither hematocrit nor clotting time (prothrombin time, Russell’s viper venom time) were differentially affected in sequentially
exposed kestrels compared to naïve birds fed low-level dietary dose of chlorophacinone. While the present findings do not reveal
lasting effects of anticoagulant exposure on blood clotting ability, findings in laboratory rats and other species have demonstrated
such effects on blood clotting, and even other molecular pathways associated with immune function and xenobiotic metabolism.
Additional studies using an environmentally realistic route of exposure and dose are underway to further test this hypothesis.
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INTRODUCTION
Over 25 years ago, Hadler and Buckle (1992) stated
that few modern pesticide groups have had such a long
history of successful use as the anticoagulant rodenticides
(ARs), and they remain one of the principal chemical
groups used in the near billion dollar global rodenticide
industry (Zion Market Research 2016). These compounds
are used worldwide for the control of vertebrate pests and
for the eradication of invasive species in ecological
restoration projects (Jacob and Buckle 2018). While their
risks to children, companion animals, and non-target
wildlife have resulted in some restrictions in application of
the more hazardous second-generation ARs (SGARs)
(Health Canada 2012, US EPA 2017), SGAR use is
allowed in many circumstances in the United States and
Canada (e.g., by permit, by professional applicator), and is
extensive in other parts of the world (Jacob and Buckle
2018).
In the past three decades, over 40 reports have appeared
in the scientific literature documenting the presence of ARs
residues in tissues of non-target predatory birds and
mammals. A summary of data from Canada, Denmark,
France, New Zealand, Spain, the United Kingdom, and the
United States indicated that over 58% of the 4,187
specimens tested contained residues of one or more AR,

principally SGARs (López-Perea and Mateo 2018). A
recent report described liver AR residues for four species
of raptors admitted to a wildlife clinic in Massachusetts
between 2012 and 2016 (Murray 2017). Ninety of the 94
liver samples contained AR residues; all 16 individuals
diagnosed with AR toxicosis contained SGAR residues;
and 74 of 78 asymptomatic birds contained SGAR
residues. Notably, 60% of the birds contained residues of
two or more SGARs, and two SGAR positive samples also
contained the first-generation ARs (FGARs) diphacinone
and chlorophacinone. Other wildlife studies have provided
evidence of individuals carrying burdens of both FGARs
and SGARs (e.g., Christensen et al. 2012, Serieys et al.
2015).
The aforementioned AR residue data indicate that
some predatory birds and mammals are exposed to ARs
on multiple occasions, and that exposed individuals may
carry AR burdens yet be seemingly asymptomatic. A
longstanding question in the fields of wildlife toxicology
and forensics is whether AR residue burdens evoke subtle
effects on body condition or physiological function. An
often cited study by Mosterd and Thijssen (1991)
demonstrated such lasting effects of the SGAR
brodifacoum. In this study, Wistar rats were orally
administered 0.2 mg brodifacoum/kg body weight (BWt).
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Prothrombin complex activity was depressed (i.e., clotting
time prolonged) for several days following exposure, but
after a week, prothrombin clotting time returned to normal.
However, activity of hepatic microsomal vitamin K
epoxide reductase (VKOR; key enzyme in vitamin K
recycling antagonized by ARs) remained depressed from
baseline activity for seemingly more than 30 days. On day
8 post-brodifacoum exposure, when clotting time was in
the normal range, rats were administered a second AR
dose (i.e., the FGAR warfarin, single subcutaneously dose
at 0.1 mg/kg BWt). While this warfarin dose caused
modest anticoagulant effects in unexposed control rats,
pronounced coagulopathy developed in brodifacoum
exposed rats on day 8 post-brodifacoum exposure. On day
25 post-brodifacoum exposure, another group of
brodifacoum–treated rats received a second AR dose
(subcutaneous 0.1 mg warfarin/kg BWt); a similar but less
dramatic effect on clotting time was observed in these rats.
These findings suggest that AR-exposed individuals, and
possibly predatory wildlife, may more readily exhibit
coagulopathy with subsequent and unintentional AR
exposure events. Such repeated exposures and
intoxications could potentially affect body condition,
physiological function and possibly even survival.
Herein we describe a somewhat similar sequential AR
exposure study using the American kestrel (Falco
sparverius) as an avian wildlife model species (Bardo and
Bird 2009) to further examine and test the hypothesis that
multiple AR exposures might affect sensitivity and
enhance intoxication caused by these compounds. The
data from our study may have application for hazard and
risk assessments of predatory birds that are repeatedly
exposed to an AR or multiple ARs while foraging in urban,
suburban and agricultural settings.
MATERIALS AND METHODS
Animals
All procedures were approved by the Institutional Animal
Care and Use Committee of the Patuxent Wildlife
Research Center, and similar to those of a previous study
(Rattner et al. 2015). In the spring of 2017, adult one to
two year old male kestrels, propagated from the colony at
Patuxent, were transferred from flight pens to small
outdoor cages (1.2 × 0.8 × 0.6 m) containing a shade roof,
perches, food tray and water bowl. Individually housed
kestrels were acclimated for three weeks, during which
time they were fed dead mice. Kestrels were then weighed
and a 0.9 ml jugular venipuncture sample was collected
into 0.1 ml of 3.2% sodium citrate from each bird for
subsequent determination of baseline clotting time.
Microhematocrit was determined and then the remainder
of each blood sample was centrifuged (2000 × g for 5
min), citrated plasma harvested, and various volumes
pipetted into cryotubes that were frozen and then stored at
-80ºC for clotting time assays. Kestrels were then shifted
to a diet of two ~35-g Classic Bird of Prey diet meatballs
(Nebraska Brand; hereafter NBP) containing the vitamin
supplement Vionate® (Gimborn, OH) for 10 days prior to
sequential AR exposure trial.
Rationale for Study Design
Information from several toxicity studies was used to

design the sequential exposure trial. Brodifacoum
mortality data was obtained from a toxicity trial in which
captive adult kestrels were fed tissue from meadow voles
(Microtus spp.) that contained various quantities of
brodifacoum (0, 0.3, 0.8, 1.6, 3.2 and 6.0 µg/g wet weight;
hereafter ww) (LaVoie 1990). Mortality occurred in one
of eight kestrels fed 0.8 µg/g ww diet, and four of eight
kestrels that received 6.0 died, with two of these exhibiting
hemorrhage. In other studies examining sublethal effects
(Rattner et al. 2016, Rattner et al. 2018), kestrels
consuming diets containing 0.3, 1.0 or 3.0 µg brodifacoum/g ww for seven days exhibited dose-dependent
bruising, overt and microscopic evidence of hemorrhage,
coagulopathy, anemia and the accumulation of hepatic
brodifacoum residues (~0.5-1.4 µg/g ww), but not
mortality. For kestrels receiving a diet containing 0.5 µg
brodifacoum/g ww for one week, coagulopathy was
apparent, but upon shifting birds to an untreated diet,
clotting time was restored to baseline values within one
week. There was no mortality, but hepatic brodifacoum
residues exceeded 0.7 µg/g ww over the course of the 28
day trial. In a study examining sublethal chlorophacinone
toxicity (Rattner et al. 2015), kestrels fed diets containing
0.15 to 1.5 µg/g ww for one week exhibited dosedependent external signs of intoxication, microscopic
evidence of hemorrhage, prolonged clotting time, and
accumulation of chlorophacinone in liver (~0.05-0.20
µg/g ww), but not mortality. Diet- and tissue-based
chlorophacinone toxicity reference values for coagulopathy were generated from this investigation. Using the
aforementioned kestrel data, we selected dietary exposure
doses for a sequential exposure trial predicted to cause
coagulopathy, but not mortality. Furthermore, the dietary
dose of brodifacoum chosen would likely result in liver
residues (> 0.7 µg/g ww, well-above the 0.1-0.2 µg/g
exposure threshold used in forensic investigations; e.g.,
Thomas et al. 2011) for an extended period of time. We
hypothesized that such SGAR residues may affect VKOR
in a manner that might affect sensitivity to subsequent AR
exposure as observed in studies in laboratory rats (Mosterd
and Thijssen 1991).
Diets Used in Exposure Trial
Several NBP diets were used in the exposure study.
These included the following: (1) control diet containing
1% corn oil vehicle; (2) chlorophacinone (CPN) diet
nominally targeted to contain 1.5 µg CPN/g ww; (3)
brodifacoum (BROD) diet nominally targeted to contain
0.5 µg BROD/g ww; and (4) CPN diet used as a challenge
exposure nominally targeted to contain 0.25 µg CPN/g
ww. The diets were formed into 25 ± 0.1-g meat balls
(overall mean ± SD moisture content for the four diets:
62.0 ± 1.1%, n = 5 meatballs/diet). The nominal 1.5 µg
CPN/g ww diet, 0.5 µg BROD/g ww diet, and the 0.25 µg
CPN/g ww challenge diet were analytically verified and
found to be (mean ± SD, n = 5) 91.5 ± 3.4%, 80.4 ± 1.6%,
and 93.5 ± 8.3% of target concentrations, respectively.
The concentrations of BROD and CPN in these test
diets are believed to be environmentally realistic for rodent
prey in proximity to AR control activities. For example,
nominal concentration of brodifacoum in the kestrel test
diet was 0.5 µg/g ww; average carcass concentrations in
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target meadow voles (Microtus pinorum) and black rats
(Rattus rattus) following field control and eradication
activities were reported to be 0.35 and 3.75 µg/g ww,
respectively (Merson et al. 1984, Pitt et al. 2015), and
estimated whole body concentrations in several species
non-target small mammals range from 0.3 to 3.6 µg/g ww
(reviewed in Shore and Coeurdassier 2018). Likewise,
nominal concentrations of CPN in kestrel test diets were
0.25 and 1.5 µg/g ww, and were within the range of
concentrations detected in carcasses of Belding’s ground
squirrels (Spermophilus beldingi), pocket gophers
(Thomomys bottae), and voles (Microtus spp.) following
field baiting trials (0.131 to 1.59 µg/g ww; Primus et al.
2001, Ramey et al 2007). A complicating factor is that
several of these values (Primus et al. 2001, Ramey et al.
2007, Pitt et al. 2015) were derived carcass samples from
which liver was removed, and may underestimate
potential exposure. Brodifacoum and chlorophacinone
residue concentrations in prey liver can be much greater
than in prey carcass (e.g., Vyas et al. 2012, Shore and
Coeurdassier 2018). Hawk species, for which the kestrel
may be the most appropriate model, do not ingest entire
mammalian prey, but selectively feed on liver, muscle and
some organs. Thus, for hawks there is uncertainty in AR
exposure based on the prey tissue preferentially consumed,
and for non-target raptors (e.g., hawks, owls) there
uncertainty in both the frequency and duration that AR
exposed prey would be consumed following a control or
eradication activity.
Sequential AR Exposure Trial
During the initial exposure period, kestrels received
either control diet, 1.5 µg CPN/g ww diet or 0.5 µg
BROD/g ww diet provided daily as two 25 ± 0.1 g
meatballs for a seven-day period (n = 6 birds/treatment).
Our previous kestrel studies have demonstrated that
consumption of these concentrations of CPN or BROD for
seven days result in pronounced coagulopathy (Rattner et
al. 2015). These 18 kestrels were then shifted to control
diet for a seven-day recovery period, followed by a seven
day challenge period during which 0.25 µg CPN/g ww diet
was provided to all 18 birds. This challenge CPN exposure
was at a dietary dose level that causes prolonged clotting
time in 10% of naïve birds (i.e., benchmark dose 10;
Rattner et al. 2015), but potentially exhibits a more
pronounced effect in animals previously exposed to
SGARs (as demonstrated in rats by Mosterd and Thijssen
1991). Hereafter, AR treatment groups are designated as
follows: control-chlorophacinone challenge (CON-CPN),
chlorophacinone-chlorophacinone challenge (CPN-CPN),
and brodifacoum-chlorophacinone challenge (BRODCPN). A group of untreated kestrels (n = 6, untreated
controls) were fed dead mice and monitored during the
study.
In this trial, birds were fed daily between 1100 and
1200 hours, and uneaten food scraps were carefully
removed from each kraft paper lined pen the following day
between 0800 and 1100 hours during both the initial
exposure and the challenge periods. The scraps were
weighed, stored, dried, and converted back to weight wet

as previously described (Rattner et al. 2015). Kestrels were
weighed at the beginning of the initial exposure period
(day 0), and both weighed and examined for signs of
bruising or external bleeding after the seven day initial
exposure period and the seven day recovery period. At the
end of the challenge period, each bird was examined,
weighed, bled (0.9 ml jugular venipuncture blood draw
into 0.1 ml 3.2% sodium citrate), sacrificed using carbon
dioxide, and then necropsied. Blood samples were also
collected from the six untreated control kestrels.
Clotting Time Assays
Prothrombin time (PT) and Russell’s viper venom time
(RVVT) of citrated kestrel plasma samples were used to
evaluate AR effects on post-translational processing of
clotting Factors II, VII, IX, and X. Thrombin clotting time
was used as an indicator of fibrinogen concentration in
plasma samples. Fibrinogen formation is insensitive to
deficiency of vitamin K-dependent clotting factors, but its
deficiency resulting from improper blood sample
collection can prolong clotting time and confound
rodenticide toxicity studies. Thus, it is important to verify
that fibrinogen concentration is adequate to promote clot
formation (>46 mg/dL in kestrels). The conduct,
performance, and use of these assays in birds have been
previously described (e.g., Rattner et al. 2010, Rattner et
al. 2015). For this study the mechanical clot endpoint was
determined using a START4 Fibrometer (Diagnostica
Stago Inc. Parsippany, NJ). The coefficient of variation of
duplicate determinations (mean ± SD) of study samples
were 0.88 ± 0.81% for PT; 2.49 ± 2.56% for RVVT; and
2.48 ±2.35% for fibrinogen.
Statistical Methods
All endpoints (body weight, weight change, CPN
consumption during challenge period, hematocrit,
fibrinogen concentration, PT, and RVVT) were tested for
homogeneity of variances and normality, and then
evaluated by one-way analysis of variance followed by
Tukey’s HSD test. The number of individuals exceeding
baseline clotting time by two standard deviations was
compared among groups using Fisher’s Exact Test. Values
presented in the text are mean ± standard deviation.
RESULTS
All kestrels (AR-exposed birds and untreated controls)
survived the initial exposure, recovery and CPN challenge
periods. At the end of the initial seven-day exposure period,
a small drop of blood was observed on the foot of a BRODexposed bird, and on day two of the recovery period, drops
of blood were observed on the rope perch of another kestrel
that had been exposed to BROD. There were no other overt
signs of intoxication or bruising in any birds during the three
study periods. At the end of the study, quality blood samples
were obtained from nearly all birds in the trial. Collection of
a jugular venipuncture sample from one kestrel in the
BROD-CPN group was unsuccessful, and this bird
succumbed moments before necropsy. At necropsy, internal
examinations of all CON-CPN, CPN-CPN, and BRODCPN birds were unremarkable.
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Table 1. Anticoagulant rodenticide consumption by kestrels during initial and challenge exposure
periods.

At the initiation of the study, body weight (n = 24
kestrels, three AR treatment groups plus untreated
controls) was 101.2 ± 4.5 g. Among these four groups of
kestrels, there were no differences in weight change (g/100
g initial BWt) on day seven (end of initial exposure, P =
0.34), day 14 (end of recovery period, P = 0.25), or day 21
(end of challenge exposure, P = 0.24). However, all groups
did exhibit a slight weight loss compared to initial body
weight over the course of the trial (CON-CPN: -4.2 ± 3.0
g/100 g; CPN-CPN: -5.5 ± 2.2 g/100g; BROD-CPN: -3.2
± 2.1 g/100 g; untreated controls: -2.1 ± 3.8 g/100 g).
Estimated daily CPN consumption during the challenge
exposure period was comparable among all three ARexposed groups (P = 0.34, Table 1).
At the initiation of the study, baseline hematocrit
averaged 47.4 ± 2.9 for the three AR treatment groups plus
the untreated controls. When birds were bled after the 21
day trial, there was no difference in hematocrit among
groups (P = 0.77; CON-CPN: 43.9 ± 2.9%; CPN-CPN:
44.8 ± 4.3%; BROD-CPN: 45.8 ± 2.0%; untreated
controls: 45.0 ± 1.7%). Fibrinogen concentration in all but
one sample was >46 mg/dL. One pre-study baseline
sample with low fibrinogen concentration (45.3 mg/dL)
had prothrombin time (23.05 sec) and Russell’s viper
venom time (42.3 sec) that were very long (>10 standard
deviations above other pre-exposure baseline samples),
and another pre-exposure sample that contained a visible
clot before assay; these samples were excluded from the
data set. All other samples seemingly had sufficient
fibrinogen to form a stable clot (discussed in Rattner et al.
2010, Rattner 2015). The average fibrinogen
concentration in baseline pre-study samples was 71.1 ±
23.4 mg/dL; at the end of the trial was 77.1 ± 21.7 mg/dL
for untreated control birds; 73.8 ± 17.7 mg/dL for the
CON-CPN group; 66.6 ± 18.3 mg/dL for the CPN-CPN
group; and 60.4 ± 9.3 mg/dL for the BROD-CPN group.
For PT, the pre-exposure baseline of all birds was 12.8
± 1.0 sec. At the end of the study, PT was similar (P =
0.70) for all groups (13.3 ± 0.8 sec untreated control birds,
13.5 ± 0.9 sec for CON-CPN, 13.0 ± 1.4 sec for CPNCPN, and 13.8 ± 1.2 sec for BROD-CPN) (Figure 1).
Using an increase in PT from pre-exposure baseline of the

mean plus two standard deviations, potentially affected
birds (i.e., respondents) had PT ≥ 14.8 sec. There were no
respondents in the untreated control and CON-CPN
groups, one of six in the CPN-CPN group, and one of five
BROD-CPN group, with no difference in number of
respondents among groups (Fishers Exact Test, P = 0.47).
For RVVT, the pre-exposure baseline for all birds was
17.1 ± 2.1 sec. At the end of the study, RVVT was similar
(P = 0.45) for all groups (19.1 ± 1.1 sec untreated control
birds, 20.1 ± 3.4 sec for CON-CPN, 18.7 ± 1.7 sec CPNCPN, and 21.0 ± 3.4 sec BROD-CPN) (Figure 1). The preexposure baseline plus two standard deviations was 21.3
sec for RVVT. Using this threshold, zero of six untreated
control birds were affected, but two of six CON-CPN, one
of six CPN-CPN, and two of five BROD-CPN birds were
affected, and there was no difference in number of
respondents among groups (P = 0.57).
DISCUSSION
Using hematocrit and blood clotting times as
endpoints, dietary exposure of captive kestrels to
environmentally realistic concentrations (Merson et al.
1984, Primus et al. 2001, Ramey et al 2007, Vyas et al.
2012, Pitt et al. 2015, Shore and Coeurdassier 2018) of the
FGAR chlorophacinone or the SGAR brodifacoum did not
affect sensitivity to a subsequent low-level dietary dose of
chlorophacinone. Based upon previous studies in kestrels
(Rattner et al. 2015), a seven-day, no-choice dietary
exposure to 1.5 µg chlorophacinone/g-ww or to 0.5 µg
brodifacoum/g ww evokes coagulopathy and results in
substantial hepatic residues of these ARs. Furthermore,
hepatic residues of brodifacoum remain elevated in
kestrels for a sustained period (months) (Rattner et al.
unpubl.), as has been demonstrated in many species of
mammals (reviewed in Horak et al. 2018). The apparent
absence of an effect of the chlorophacinone challenge dose
in kestrels was in contrast to that elicited by a warfarin
challenge dose in brodifacoum treated rats (Mosterd and
Thijssen 1991), and may be due to species difference in
AR pharmacokinetics or VKOR activity and its inhibition.
However, available tissue clearance and VKOR kinetic
data comparing birds to laboratory rodents are too limited
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Figure 1. Prothrombin time and Russell’s viper venom time in seconds. Bar is mean ± standard
deviation, “o” are individual observations, ……. (dotted line) = baseline mean and ------ (dashed line)
= baseline mean plus two standard deviations.

(Watanabe et al. 2010, Watanabe et al. 2015) to firmly
draw such a conclusion. Alternatively, the chlorophacinone challenge dose used in the present study could
have been too low to clearly detect such an effect. To test
the latter hypothesis, we are currently repeating this kestrel
exposure study using a greater chlorophacinone challenge
dose (0.75 µg /g ww diet, benchmark dose 90; Rattner et
al. 2015).
The results of the present study do not refute findings
in the laboratory rat (Mosterd and Thijssen 1991)
demonstrating that exposure to an SGAR can have lasting
effects on VKOR activity and blood clotting function.
Somewhat similar effects have also been observed in
Japanese quail (Coturnix japonica) sequentially exposed
to SGARs (Butler 2010). Quail administered brodifacoum
as a single oral dose in corn oil (200 or 400 µg/kg BWt),
and then 26 days later with a second gavage dose of
brodifacoum (200 µg/kg BWt), exhibited longer clotting
time and more protracted coagulopathy than quail
receiving only a single brodifacoum dose. While the

brodifacoum exposure doses in rat, quail, and the kestrel
studies were comparable (200 or 400 µg/kg BWt versus
cumulative seven-day dose of ~528.5 µg/kg BWt), the
challenge compounds (i.e., FGAR warfarin, SGAR
brodifacoum versus FGAR chlorophacinone), and
exposures method differed (subcutaneous injection in rats,
single oral dose in quail versus multi-day dietary exposure
in kestrels), and could also account for disparate findings.
Exposure via the diet is seemingly more
environmentally realistic than single subcutaneous
exposure in rats and single oral dose in quail. While we do
not necessarily dispute the findings of coagulopathy in the
quail, it is noteworthy that the clotting assay methodologies and their precision vastly differed between studies
(i.e., single PT determinations, lengthy control clotting
time, and precision not specified in Butler 2010, versus
high precision in PT and RVVT assays, short clotting
times, and fibrinogen determination to rule out nonspecific
effects in present kestrel study). Clotting time assays and
reagents for use in birds have yet to be standardized, which
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is particularly challenging for studies assessing AR effects
in captive and free-ranging raptors (Harr 2010, Rattner et
al. 2010, Webster et al. 2015).
One of the critical information gaps in assessing the
risk of ARs to non-target species is the potential for long
lasting effects that might alter body condition, survival and
recruitment (Rattner et al 2014). While coagulopathy
could influence both individual- and population-level
parameters, there is recent evidence that AR exposure can
affect disease susceptibility, immune function, and a
myriad of other effects in mammals independent of
coagulopathy (Rattner et al. 2014, Fraser et al. 2018,
Serieys et al. 2018). Because of the likelihood and
environmental relevance of exposure to multiple FGARs
and SGARs, additional investigation of potential sublethal
effects is warranted.
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